These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24129691)

  • 21. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
    Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracranial hypertension following intrathecal administration of liposomal cytarabine.
    Lunskens S; Lammertijn L; Deeren D; Bergmans B; Maertens J; Vandenberghe R
    J Neurol; 2011 Jan; 258(1):162-3. PubMed ID: 20706845
    [No Abstract]   [Full Text] [Related]  

  • 25. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model.
    Thomsen AM; Gulinello ME; Wen J; Schmiegelow K; Cole PD
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):e91-e96. PubMed ID: 28654460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.
    Mrugala MM; Kim B; Sharma A; Johnson N; Graham C; Kurland BF; Gralow J
    Clin Breast Cancer; 2019 Oct; 19(5):311-316. PubMed ID: 31175053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
    Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents].
    Moreno L; García Ariza MA; Cruz O; Calvo C; Fuster JL; Salinas JA; Moscardo C; Portugal R; Merino JM; Madero L
    An Pediatr (Barc); 2016 Nov; 85(5):274.e1-274.e8. PubMed ID: 27086069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
    Parasole R; Menna G; Marra N; Petruzziello F; Locatelli F; Mangione A; Misuraca A; Buffardi S; Di Cesare-Merlone A; Poggi V
    Leuk Lymphoma; 2008 Aug; 49(8):1553-9. PubMed ID: 18766969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration.
    Butto A; Al-Holou WN; Junck L; Sagher O; Fletcher JJ
    J Clin Neurosci; 2011 Oct; 18(10):1417-8. PubMed ID: 21764318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia.
    Levinsen M; Harila-Saari A; Grell K; Jonsson OG; Taskinen M; Abrahamsson J; Vettenranta K; Åsberg A; Risteli J; Heldrup J; Schmiegelow K
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):602-609. PubMed ID: 27571129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rationale for the use of liposomal cytarabine in meningeal carcinomatosis].
    Boiardi A
    Tumori; 2007; 93(3):suppl 1-3. PubMed ID: 17679478
    [No Abstract]   [Full Text] [Related]  

  • 33. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature.
    Seif AE; Reilly AF; Rheingold SR
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e349-52. PubMed ID: 20962675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
    Vazquez Fuster IB; Taylor AR; Smith AN; Duran SH; Ravis WR; Jasper SL; Arnold RD
    J Vet Intern Med; 2020 Jul; 34(4):1563-1569. PubMed ID: 32442344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
    Stacchini A; Demurtas A; Aliberti S
    Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
    González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
    Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma.
    Gállego Pérez-Larraya J; Palma JA; Carmona-Iragui M; Fernández-Torrón R; Irimia P; Rodríguez-Otero P; Panizo C; Martínez-Vila E
    J Neurooncol; 2011 Jul; 103(3):603-9. PubMed ID: 20953897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
    Kim S; Chatelut E; Kim JC; Howell SB; Cates C; Kormanik PA; Chamberlain MC
    J Clin Oncol; 1993 Nov; 11(11):2186-93. PubMed ID: 8229133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
    Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
    Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma.
    Ostermann K; Pels H; Kowoll A; Kuhnhenn J; Schlegel U
    J Neurooncol; 2011 Jul; 103(3):635-40. PubMed ID: 20953896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.